Phase 3Active, not recruiting
Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)
A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou (Academic or other)
- Enrolment
- 707 enrolled
- Conditions
- HNSCC
- Interventions
- Cetuximab; avelumab; Cisplatin; IMRT
- Ages
- adults, older adults
- Registry
- NCT02999087
From the registry
The purpose of this study is to demonstrate that treatment with avelumab in combination with RT-cetuximab is superior to standard of care (SOC) cisplatin-RT and/or to SOC RT-cetuximab alone in terms of progression-free survival (PFS) in front-line patients with locally advanced SCCHN.
Primary outcomes
- Progression free survival